Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29798986 | 1.00 | ERAP1 (0.51) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL23641666 | 0.98 | ERAP1 (0.49) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| Bromide SCHEMBL5145384 | 0.96 | ERAP1 (0.47) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28409885 | 0.96 | ERAP1 (0.47) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL31093213 | 0.91 | ERAP1 (0.47) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL26106884 | 0.91 | ERAP1 (0.47) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL1049324 | 0.75 | ERAP1 (0.50) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| Water SCHEMBL21823213 | 0.73 | ERAP1 (0.49) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| Iodide SCHEMBL9134481 | 0.73 | PTPN1 (0.50) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL13173865 | 0.73 | ERAP1 (0.53) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20260062461-A1 | POPULATION OF ANTIBODIES COMPRISING HOMOGENEOUS ANTIBODIES EACH HAVING LEFT-RIGHT ASYMMETRIC SUGAR CHAINS, AND METHOD FOR PRODUCING SAME | RIKEN (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4703474-A1 | ANTI-LRRC15 ANTIBODY | Daiichi Sankyo Company, Limited (JP) | 2026-03-04 | — | — | EP | disclosed |
| EP-4678192-A1 | DOUBLE SITE-DIRECTED ANTIBODY-FUNCTIONAL MOLECULAR CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676483-A1 | IMPROVED LINKER-PAYLOADS FOR ANTIBODY CONJUGATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF | OBI Pharma, Inc. (TW) | 2026-01-14 | — | — | EP | disclosed |
| US-20260008803-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | ACADEMIA SINICA (TW) | 2026-01-08 | — | — | US | disclosed |
| US-20250320255-A1 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | DESIGN ZYME LLC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4615990-A1 | GLYCOSYNTHASE VARIANTS FOR ANTIBODY-DRUG CONJUGATE ENGINEERING | OBI Pharma, Inc. (TW) | 2025-09-17 | — | — | EP | disclosed |
| US-12384811-B2 | Sialidase-resistant saccharide and method of making and using the same | ACADEMIA SINICA (TW) | 2025-08-12 | — | — | US | disclosed |
| US-20250228958-A1 | TSP1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-2407461-B1 | PROCESS FOR PREPARATION OF 1-ALKYL-5-BENZOYL-1H-TETRAZOLE DERIVATIVES | NIPPON SODA CO (JP) | 2016-05-18 | — | — | EP | disclosed |
| EP-2392566-B1 | METHOD FOR PRODUCING DICHLOROPYRAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-8835636-B2 | Method for producing dichloropyrazine derivative | NIPPON SODA CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20140024832-A1 | METHOD FOR PRODUCING DICHLOROPYRAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8586741-B2 | Method for producing dichloropyrazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8273781-B2 | Process for preparation of 1-alkyl-5-benzoyl-1H-tetrazole derivatives | NIPPON SODA CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2407461-A1 | PROCESS FOR PREPARATION OF 1-ALKYL-5-BENZOYL-1H-TETRAZOLE DERIVATIVES | Nippon Soda Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20120004420-A1 | PROCESS FOR PREPARATION OF 1-ALKYL-5-BENZOYL-1H-TETRAZOLE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| EP-2392566-A1 | METHOD FOR PRODUCING DICHLOROPYRAZINE DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2011-12-07 | — | — | EP | disclosed |
| US-20110275817-A1 | METHOD FOR PRODUCING DICHLOROPYRAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062461-A1 | POPULATION OF ANTIBODIES COMPRISING HOMOGENEOUS ANTIBODIES EACH HAVING LEFT-RIGHT ASYMMETRIC SUGAR CHAINS, AND METHOD FOR PRODUCING SAME | FCGR2A, FCGR3B, FCGR1A | ERAP1 132/4885KDM4E 1917/4885MAPT 3217/4885 |
| US-20110275817-A1 | METHOD FOR PRODUCING DICHLOROPYRAZINE DERIVATIVE | CBR3, CBR1, HDHD5 | ERAP1 3286/4885KDM4E 1636/4885MAPT 4539/4885 |
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | SIGLEC9, DSG1, VSIG8 | ERAP1 2790/4885KDM4E 3835/4885MAPT 2345/4885 |
| US-20120004420-A1 | PROCESS FOR PREPARATION OF 1-ALKYL-5-BENZOYL-1H-TETRAZOLE DERIVATIVES | KCNMA1, KCNA5, KCNK5 | ERAP1 3517/4885KDM4E 180/4885MAPT 3696/4885 |
| US-20250320255-A1 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | B3GNT2, ST3GAL3, MUC1 | ERAP1 2758/4885KDM4E 4709/4885MAPT 3320/4885 |
| US-20260008803-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | NEU2, ST6GAL1, NEU3 | ERAP1 819/4885KDM4E 3272/4885MAPT 2734/4885 |
| US-12384811-B2 | Sialidase-resistant saccharide and method of making and using the same | NEU2, NEU3, NEU1 | ERAP1 434/4885KDM4E 2451/4885MAPT 4094/4885 |
| US-20140024832-A1 | METHOD FOR PRODUCING DICHLOROPYRAZINE DERIVATIVE | CBR3, CBR1, HDHD5 | ERAP1 3286/4885KDM4E 1636/4885MAPT 4539/4885 |
| US-20250228958-A1 | TSP1 INHIBITOR | ANXA11, SERPINC1, NPR1 | ERAP1 270/4885KDM4E 4118/4885MAPT 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.